Google's life sciences sister company Verily announces layoffs, cuts devices program; Read memo

Alphabet’s life sciences and healthcare subsidiary — Verily has announced a major restructuring which includes layoffs along with complete elimination of its

medical device program

. According to a report by Business Insider, the company CEO Stephen Gillet, conveyed this decision to the staff via in internal memo. In the memo shared with employees Gillet acknowledged the gravity of the decision, writing, ’The path forward requires difficult decisions’. The CEO also praised the contributions of the Devices team, many of whom had spent decades in developing innovations such as the

Dexcom G7 glucose monitor

, retinal imaging tools, and clinical study wearables.Verily has confirmed the discontinuation of manufacturing and support for medical devices. The company has not yet disclosed the exact number of employees laid off. Also, the company said that it will continue supporting the innovations such as the Dexcom G7 glucose monitor, retinal imaging tools, and clinical study wearables. A Verily spokesperson told Business Insider that the company is making “deliberate choices about resourcing” to accelerate its path to commercial success.

Read the complete memo shared by Verily CEO Stephen Gillet

Veeps,I'm writing to share some difficult news. Today we have made workforce reductions across the company as part of our ongoing efforts to manage costs and ensure resources are allocated to our most critical priorities. All impacted Veeps have been notified.

These are not decisions we've taken lightly, and I want to address both those who will be impacted and those who will continue with us on Verily's journey.A significant part of these changes is the decision to wind down our Devices program. Over the years, Verily has built a legacy in developing world-class, innovative medical devices. The dedicated professionals in our Devices organizations — many who have devoted a decade or more to this important work — have poured their hearts, expertise, and commitment into advancing healthcare technology. To everyone who contributed to this program, whether as a core team member or in a supporting role across the company, your efforts have been extraordinary. You've led groundbreaking achievements, from the launch of the Dexcom G7 CGM, to the Stargazer VNRC launch with other 7,800 patients screened, to Study Devices launched with numerous study partners, and these contributions have advanced patient care and medical research.As Verily has continued on its journey of narrowing product focus around our precision health platform, and data and AI strategy, we cannot support the investment of the resources necessary for the long-term growth and scaling of our Devices programs, and have therefore made the difficult decision to fully wind down the program. We will continue to honor our commitments by supporting customers using the Numetric Watch in active clinical trials.To all of our departing Veeps: Your contributions to programs across our business have been invaluable to Verily's mission and have made a lasting mark on the healthcare technology landscape. The innovation, dedication, and collaborative spirit you've brought to your work have advanced our company and touched many lives. We are grateful for everything you've given to Verily and to the patients and partners we serve together.To our continuing team members: I know this news is difficult to process, especially as we say goodbye to colleagues and friends. Your continued dedication during this transition period is both appreciated and essential as we focus our efforts on our core mission. The work ahead of us in precision health, data, and AI remains as important and exciting as ever, and we need your expertise and commitment to continue making a meaningful different in healthcare. We will be providing additional details about what today's changes mean for Verily and for you and your teams in the coming days, both within your respective functions and in our next town hall.During this challenging time, I ask for your patience and understanding as we prioritize supporting our departing colleagues in the days ahead. To everyone — whether you're leaving us or continuing with Verily — thank you for your professionalism, your contributions, and your commitment to our shared mission of using technology to improve human health.The path forward requires difficult decisions, but I remain confident in Verily's future and grateful for the exceptional team that will continue building it.